. Author manuscript; available in PMC: 2020 Apr 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2019 Aug 6;28(10):1755–1764. doi: 10.1158/1055-9965.EPI-19-0526

Table 2.

Distributions of serum concentrations of PBDE flame retardants in female papillary thyroid cancer cases and controls.

				Serum Concentrations (ng/g lipd)
Chemical name (abbreviation)	Estimated Half-Life (yr)^a	Median Limit of Detection (LOD)	% > LOD	Cases (n=250)		Controls (n=250)
Chemical name (abbreviation)	Estimated Half-Life (yr)^a	Median Limit of Detection (LOD)	% > LOD	Median	25^th–75^th percentile	Median	25^th–75^th percentile
2,2’,4-Tribromodiphenyl ether (BDE-17)	NI	0.17	4	<LOD^b	<LOD^b	<LOD^b	<LOD^b
2,4,4’-Tribromodiphenyl ether (BDE-28)	3.0	0.20	82	0.44	0.22 – 0.73	0.51	0.26 – 1.0
2,2’,4,4’-Tetrabromodiphenyl ether (BDE-47)	1.4–3.0	0.39	99	6.36	3.45 – 10.94	7.28	4.04 – 15.33
2,2’,3,4,4’-Pentabromodiphenyl ether (BDE-85)	NI	0.18	33	<LOD^a	<LOD^a	<LOD^a	<LOD^a
2,2’,4,4’,5-Pentabromodiphenyl ether (BDE-99)	5.4	0.22	95	1.04	0.54 – 1.74	1.21	0.66 – 2.74
2,2’,4,4’,6-Pentabromodiphenyl ether (BDE-100)	1.8–2.9	0.17	98	1.27	0.69 – 2.33	1.47	0.78 – 2.86
2,2’,4,4’,5,5’-Hexabromodiphenyl ether (BDE-153)	7.4–11.7	0.17	100	3.04	1.77 – 6.01	3.08	2.02 – 5.86
2,2’,4,4’,5,6’-Hexabromodiphenyl ether (BDE-154)	5.8	0.16	37	<LOD^a	<LOD^a	<LOD^a	<LOD^a
2,2’,3,4,4’,5’,6-Heptabromodiphenyl ether (BDE-183)	0.26–0.30	0.16	28	<LOD^a	<LOD^a	<LOD^a	<LOD^a
Decabromodiphenyl ether (BDE-209)	0.04–0.07	0.83	84	1.47	1.04 – 2.14	1.55	1.00 – 2.41
2,2’,4,4’,5,5’-Hexabromobiphenyl (BB-153)	13–29	0.17	97	1.40	0.82 – 2.33	1.45	0.94 – 2.44

Half-lives compiled from Geyer et al. 2004 (50), McDonald et al. 2005 (62), Thuresson et al. 2006 (51), Blanck et al. 2000 (63). NI indicates a half-life was not identified for that congener in the literature.

Median and quartile limits not calculated because <60% detection frequency for this compound.